Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F, Oksuzoglu B, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: berk v. J Chemother. 2014 Oct;26(5):300-5. doi: 10.1179/1973947813Y.0000000147. Epub 2013 Dec 6. J Chemother. 2014. PMID: 24112786
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isıkdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: berk v. Onkologie. 2012;35(12):740-5. doi: 10.1159/000345040. Epub 2012 Oct 31. Onkologie. 2012. PMID: 23207619 Free article.
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isıkdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpacı E, Benekli M; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: berk v. J Chemother. 2012 Aug;24(4):217-20. doi: 10.1179/1973947812Y.0000000020. J Chemother. 2012. PMID: 23040686
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A, Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: berk v. J Cancer Res Clin Oncol. 2013 Jun;139(6):981-6. doi: 10.1007/s00432-013-1409-1. Epub 2013 Mar 5. J Cancer Res Clin Oncol. 2013. PMID: 23463098 Clinical Trial.
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO). Kaya AO, et al. Among authors: berk v. Asian Pac J Cancer Prev. 2012;13(2):463-7. doi: 10.7314/apjcp.2012.13.2.463. Asian Pac J Cancer Prev. 2012. PMID: 22524807 Free article.
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Yildiz R, et al. Among authors: berk v. J Cancer Res Clin Oncol. 2012 Nov;138(11):1845-52. doi: 10.1007/s00432-012-1264-5. Epub 2012 Jun 22. J Cancer Res Clin Oncol. 2012. PMID: 22722713
Clinicopathological features in bilateral breast cancer.
Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M. Baykara M, et al. Among authors: berk v. Asian Pac J Cancer Prev. 2012;13(9):4571-5. doi: 10.7314/apjcp.2012.13.9.4571. Asian Pac J Cancer Prev. 2012. PMID: 23167382 Free article.
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology. Uncu D, et al. Among authors: berk v. Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7. Oncology. 2013. PMID: 23392240 Clinical Trial.
73 results